Joseph Baroldi, serving as Executive Vice President and Chief Business Officer at Ionis Pharmaceuticals Inc. (NASDAQ: IONS), has disclosed insider trading activity involving his spouse on June 26, 2026. The transaction details reveal that the spouse sold 5,635 shares of the company's common stock, realizing a total value of $451,698. The sale was executed at a weighted average price of $80.1595, with individual transaction prices fluctuating between $80.00 and $80.52. This divestment was carried out under the framework of a Rule 10b5-1 trading plan, which was originally adopted by Mr. Baroldi’s spouse on November 25, 2025. The timing of this sale is notable as IONS stock is trading near its 52-week high of $86.74, a level reached following a substantial 101% return over the past year. Despite the recent price appreciation, the stock currently trades at $79.30, and analysis from InvestingPro suggests that the company may be overvalued at these current price levels.
In a concurrent transaction on the same day, Mr. Baroldi’s spouse acquired a total of 5,635 shares of common stock through the exercise of non-qualified stock options. This acquisition was valued at $277,180 and was composed of two distinct tranches: 3,866 shares purchased at $56.78 per share and 1,769 shares purchased at $32.6 per share. Following these combined activities, the spouse maintains an indirect holding of 4,669 shares of Ionis Pharmaceuticals common stock. Additionally, Mr. Baroldi himself directly holds 48,522 shares of the company's common stock. These transactions were formally reported in a Form 4 filing submitted to the Securities and Exchange Commission on June 30, 2026.
Beyond the insider trading activity, Ionis Pharmaceuticals has reported significant operational milestones. The company received regulatory approval from the U.S. Food and Drug Administration for its drug Tryngolza (olezarsen). This approval was granted under the Priority Review pathway and targets adults with severe hypertriglyceridemia, specifically those with triglyceride levels at or above 500 mg/dL. The therapeutic aims to reduce triglycerides and lower the risk of acute pancreatitis. Tryngolza is available in 50 mg or 80 mg doses and is administered monthly via autoinjector. It is also approved for adults with familial chylomicronemia syndrome, a rare form of severe hypertriglyceridemia.
The regulatory approval has prompted positive responses from several financial analysts. H.C. Wainwright raised its price target for Ionis to $130, maintaining a Buy rating. Needham reiterated a Buy rating with a $105 price target, and Oppenheimer maintained an Outperform rating with a $110 price target. Both firms emphasized the drug’s unique therapeutic benefits as a key driver for this optimism.
In addition to the FDA approval, Ionis Pharmaceuticals announced the appointment of Ludwig Hantson to its board of directors. Hantson brings over 30 years of experience in the biopharmaceutical industry, having previously served as CEO of Alexion. These developments reflect significant progress and strategic growth for Ionis Pharmaceuticals. The stock data indicates a current price of $79.30, with a recent decline of 1.39 points or 1.72% as of the last close at 15:59:59. After hours trading shows a price of $79.29 with no change. Investors seeking deeper insights into IONS can access a detailed Pro Research Report on InvestingPro, which includes 10 additional ProTips and comprehensive financial analysis.